CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,024 enrolled
Drug / intervention
Dactolisib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04668352
NCT04668352Phase 3Completed
CompareCT.gov

A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

Restorbio Inc.·interventional·Posted Dec 16, 2020·Updated Jun 23, 2021

In Brief

A Phase 3 clinical trial evaluating Dactolisib and Placebo for Respiratory Tract Infections. Completed, enrolled 1,024 participants across 1 site.

Detailed Summary

To determine if RTB101 as compared to placebo decreases the percentage of subjects with clinically symptomatic respiratory illness (with or without an associated laboratory-confirmed pathogen) through Week 16.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Tract Infections
CountriesNew Zealand
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedDec 16, 2020
Enrollment StartApr 15, 2019
Primary CompletionDec 2, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.5 years ago

Interventions

Dactolisibdrug

TORC1 inhibitor

Placeboother

Placebo